CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
Retrieved on:
Wednesday, November 1, 2023
McWherter, Liver injury, Patient, University of Texas Southwestern Medical Center, AST, MD, Conditional sentence, Liver, Professor, ALP, PBC, Bilirubin, Vierling, Alkaline phosphatase, Cholestasis, Primary biliary cholangitis, University, Safety, Alimentary Pharmacology & Therapeutics, Therapy, ALT, Diagnosis, Liver disease, Pharmaceutical industry, DA, RJ, Y, PJ
Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.
Key Points:
- Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.
- The objectives were to evaluate the long-term safety, tolerability, and efficacy of seladelpar at 5 mg and 10 mg once daily throughout 2-years.
- In addition, ALP normalization was achieved in 23% and 42% in patients at one and two years, respectively.
- In the study long-term treatment with seladelpar resulted in continued improvement in markers of cholestasis and liver injury in the second year of treatment.